Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.
Actively Recruiting
Healthy Volunteer
Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.
Actively Recruiting
Researchers are studying children aged 12 to less than 18 years with asthma to compare the safety and effectiveness of a combination inhaler called QVM149 which includes indacaterol acetate, glycopyrronium bromide, and mometasone furoate against another inhaler combining salmeterol xinafoate and fluticasone propionate. The study is designed as a randomized, double-blind, crossover trial lasting 36 weeks to see how these treatments affect lung function and asthma control. Participants will first go through a screening period up to 15 days, followed by a 14-day run-in phase using salmeterol xinafoate with fluticasone propionate. Then, they will receive two treatment periods of 12 weeks each one period with QVM149 once daily plus a placebo matching the comparator inhaler, and another period with the comparator inhaler twice daily plus a placebo matching QVM149. A 3-week washout period separates these treatment phases. After completing treatments, participants enter a 30-day safety follow-up while returning to their usual asthma care. During the study, participants will attend regular visits to assess lung function using FEV1 measurements, asthma control through questionnaires, quality of life, and rescue medication use. Researchers will also track any asthma exacerbations and monitor safety by recording adverse events throughout the treatment and follow-up. The total study duration for each participant is approximately 36 weeks.
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.
Actively Recruiting
Men tend to have worse outcomes throughout the tuberculosis TB care process, including less symptom reporting, diagnosis, and treatment completion, especially when also living with HIV. This research evaluates the feasibility of Coach Mpilo CM, a peer-support intervention originally designed to help men with HIV, adapted here for men with TB and TBHIV co-infection. The study aims to assess how well this coaching model works for men starting TB treatment and for those co-infected with HIV, focusing on treatment completion and viral suppression as key outcomes. The study includes two main groups men beginning TB treatment who receive either the CM peer support or usual clinic-based care, and men co-infected with TB and HIV who receive the adapted CM support or standard care. The CM intervention involves trained peer coaches with personal experience in TB and HIV treatment providing support and guidance to help men stay on their treatment plans. Participants will be randomized to either the CM support or standard care in a controlled trial. Participants will be followed through their TB treatment and beyond, with assessments of how feasible, acceptable, and safe the CM intervention is for men. Researchers will measure TB treatment completion within 180 days and, for those with HIV, adherence to antiretroviral therapy and viral load suppression up to 210 days. The study involves interviews, simulations, and monitoring of treatment progress to gather data on outcomes and inform future larger trials. Total participation lasts through treatment and follow-up periods of about 6 to 7 months.
Actively Recruiting
Researchers are evaluating the safety and bactericidal activity of TBD09 combined with other drugs in adults with drug-sensitive pulmonary tuberculosis. This Phase 2 randomized trial aims to determine if these combinations are safe and effective for treating this form of tuberculosis. The study is sponsored by the Gates Medical Research Institute and involves multiple treatment groups with varying doses of TBD09. Participants are assigned to one of five groups receiving different combinations of TBD09, bedaquiline, pretomanid, and linezolid. The TBD09 doses vary from 100 mg three times weekly to 500 mg daily, combined with bedaquiline and pretomanid, or linezolid with bedaquiline and pretomanid. Treatment lasts for 28 days in each group. During the study, participants will be monitored through Day 35 for safety, including serious adverse events, treatment-emergent adverse events, and adverse events leading to treatment discontinuation. Researchers will also assess bactericidal activity up to Day 28 and study pharmacokinetics of TBD09. Additional safety evaluations include blood tests, visual and color vision assessments, and peripheral neuropathy screening. The total participation period covers screening, treatment, and follow-up assessments.
1-10 of 17
1